scholarly journals 7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir

2018 ◽  
Vol 130 (24) ◽  
pp. 7299-7303 ◽  
Author(s):  
Robert E. Ziegler ◽  
Bimbisar K. Desai ◽  
Jo-Ann Jee ◽  
B. Frank Gupton ◽  
Thomas D. Roper ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Hiv Integrase ◽  
Flow Synthesis ◽  
Step Flow

scholarly journals Berichtigung: 7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir

2018 ◽  
Vol 130 (46) ◽  
pp. 15185-15185
Author(s):  
Robert E. Ziegler ◽  
Bimbisar K. Desai ◽  
Jo‐Ann Jee ◽  
B. Frank Gupton ◽  
Thomas D. Roper ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Hiv Integrase ◽  
Flow Synthesis ◽  
Step Flow

scholarly journals Corrigendum: 7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir

2018 ◽  
Vol 57 (46) ◽  
pp. 14969-14969
Author(s):  
Robert E. Ziegler ◽  
Bimbisar K. Desai ◽  
Jo‐Ann Jee ◽  
B. Frank Gupton ◽  
Thomas D. Roper ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Hiv Integrase ◽  
Flow Synthesis ◽  
Step Flow

scholarly journals 7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir

2018 ◽  
Vol 57 (24) ◽  
pp. 7181-7185 ◽  
Author(s):  
Robert E. Ziegler ◽  
Bimbisar K. Desai ◽  
Jo-Ann Jee ◽  
B. Frank Gupton ◽  
Thomas D. Roper ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Hiv Integrase ◽  
Flow Synthesis ◽  
Step Flow

Novel Second Generation HIV Integrase Inhibitor-DOLUTEGRAVIR: An Emerging Weapon Against HIV

2017 ◽  
Vol 14 (3) ◽  
pp. 354-371 ◽  
Author(s):  
Vivek Jain ◽  
Diksha Gupta ◽  
Ashutosh Pareek ◽  
Yashumati Ratan
Keyword(s):  
Second Generation ◽  
Integrase Inhibitor ◽  
Hiv Integrase

scholarly journals No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments

2021 ◽  
Author(s):  
Basma Abdi ◽  
Mouna Chebbi ◽  
Marc Wirden ◽  
Elisa Teyssou ◽  
Sophie Sayon ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Routine Care ◽  
Biological Data ◽  
Recombinant Form ◽  
Hiv Integrase ◽  
Resistance Mutations ◽  
Clinical Routine ◽  
Inhibitor Resistance ◽  
Hiv 1

Abstract Background Little is known about HIV-1 integrase inhibitor resistance in the CNS. Objectives This study aimed to evaluate integrase inhibitor resistance in CSF, as a marker of the CNS, and compare it with the resistance in plasma. Methods HIV integrase was sequenced both in plasma and CSF for 59 HIV-1 patients. The clinical and biological data were collected from clinical routine care. Results Among the 59 HIV-1 patients, 32 (54.2%) were under antiretroviral (ARV) treatment. The median (IQR) HIV-1 RNA in the plasma of viraemic patients was 5.32 (3.85–5.80) and 3.59 (2.16–4.50) log10 copies/mL versus 4.79 (3.56–5.25) and 3.80 (2.68–4.33) log10 copies/mL in the CSF of ARV-naive and ARV-treated patients, respectively. The patients were mainly infected with non-B subtypes (72.2%) with the most prevalent recombinant form being CRF02_AG (42.4%). The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively. Integrase inhibitor resistance mutations in CSF were similar to those in plasma, except for 1/59 patients. Conclusions This work shows similar integrase inhibitor resistance profiles in the CNS and plasma in a population of HIV-1 viraemic patients.

Radiosynthesis of the HIV integrase inhibitor [18F]MK-0518 (Isentress)

2010 ◽  
pp. n/a-n/a ◽  
Author(s):  
Wenping Li ◽  
Wayne Thompson ◽  
Thorsten Fisher ◽  
John S. Wai ◽  
Daria Hazuda ◽  
...  
Keyword(s):  
Integrase Inhibitor ◽  
Hiv Integrase

scholarly journals Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir

Molecules ◽  
2021 ◽  
Vol 26 (23) ◽  
pp. 7178
Author(s):  
Yanqiang Han ◽  
Hongyuan Luo ◽  
Qianqian Lu ◽  
Zeying Liu ◽  
Jinyun Liu ◽  
...  
Keyword(s):  
Crystal Structure ◽  
Ab Initio ◽  
Crystal Structures ◽  
Structure Prediction ◽  
Hiv Infections ◽  
Integrase Inhibitor ◽  
Hiv Integrase ◽  
Stability Evaluation ◽  
The Stability ◽  
Long Acting

The long-acting parenteral formulation of the HIV integrase inhibitor cabotegravir (GSK744) is currently being developed to prevent HIV infections, benefiting from infrequent dosing and high efficacy. The crystal structure can affect the bioavailability and efficacy of cabotegravir. However, the stability determination of crystal structures of GSK744 have remained a challenge. Here, we introduced an ab initio protocol to determine the stability of the crystal structures of pharmaceutical molecules, which were obtained from crystal structure prediction process starting from the molecular diagram. Using GSK744 as a case study, the ab initio predicted that Gibbs free energy provides reliable further refinement of the predicted crystal structures and presents its capability for becoming a crystal stability determination approach in the future. The proposed work can assist in the comprehensive screening of pharmaceutical design and can provide structural predictions and stability evaluation for pharmaceutical crystals.

Sign in / Sign up

Export Citation Format

Share Document